Compositions and methods for inhibiting growth and metastasis of melanoma
There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.
1. A method for inhibiting melanoma growth, comprising contacting the melanoma with an effective amount of a celastrol derivative, wherein the celastrol derivative is selected from the group consisting of compounds II, IV-VIII, and XII-XV:
2. The method of claim 1 , wherein the celastrol derivative is selected from the group consisting of compounds XIII and XV.
3. The method of claim 1 , wherein the contacting is via topical administration or subcutaneous administration.
4. The method of claim 1 , wherein the celastrol derivative is formulated in a pharmaceutical composition.
5. A method for inhibiting melanoma metastasis comprising contacting the melanoma with an effective amount of a celastrol derivative, wherein the celastrol derivative is selected from the group consisting of compounds II, IV-VIII, XII-XV:
6. The method of claim 5 , wherein the celastrol derivative is selected from the group consisting of compounds XIII and XV.
7. A method of sensitizing melanoma cells to apoptosis comprising contacting the cells with an effective amount of a celastrol derivative, wherein the celastrol derivative is selected from the group consisting of compounds II, IV-VIII, XII-XV:
8. The method of claim 7 , wherein the celastrol derivative is selected from the group consisting of compounds XIII and XV.
9. A method of treating melanoma in a subject in need thereof comprising administering an effective amount of a celastrol derivative, wherein the celastrol derivative is selected from the group consisting of compounds II, IV-VIII, and XII-XV:
10. The method of claim 9 , wherein the administering is via topical administration or subcutaneous administration.
11. The method of claim 9 , wherein celastrol derivative is formulated in a pharmaceutical composition.
12. The method of claim 9 , wherein the celastrol derivative is selected from compounds XIII and XV.